RxDoctor Payments Data

Kevin Schendel, MD

Internal Medicine · Baltimore, MDNPI 1992741789

Payments from drug & device makers

$35,228in general payments, 2019–2025

Across 1,002 payments — averaging $35.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$12K
  • Johnson & Johnson$9K
  • AbbVie$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$2K
  • Amgen$1K
  • plus $7K from 35 others

What the payments were for

  • Consulting fees$9,83828%
  • Speaking & faculty fees$7,94723%
  • Travel & lodging$1,7585%
  • Food & beverage$15,38544%
  • Education$3011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,228 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$266,817
Medicare patients
661
Services billed
4,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$103,119
OzempicSemaglutide53$66,530
GlyxambiEmpagliflozin/Linagliptin52$61,077
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$54,030
JardianceEmpagliflozin48$47,670
RybelsusSemaglutide17$36,163
JanuviaSitagliptin Phosphate26$34,703
XareltoRivaroxaban16$25,938
MounjaroTirzepatide16$22,690
FarxigaDapagliflozin Propanediol18$18,183
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$13,576
Repatha SureclickEvolocumab15$13,305
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$12,737
MyrbetriqMirabegron12$12,122
Tresiba Flextouch U-100Insulin Degludec14$8,632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimGlyxambi, Jardiance$727$108,747100 claims
PfizerEliquis$645$103,11984 claims
Novo NordiskOzempic, Rybelsus$12,466$102,69370 claims
GSKTrelegy Ellipta, Anoro Ellipta$395$67,60678 claims
MerckJanuvia, Belsomra$520$42,57645 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,530$29,19242 claims
Johnson & JohnsonXarelto$8,982$25,93816 claims
Lilly USA, LLCMounjaro$1,758$22,69016 claims
Astellas Pharma US IncMyrbetriq$359$12,12212 claims
NovartisEntresto$295$8,47213 claims
AbbVieSynthroid$2,325$4,35174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →